

Name: Ross McLeod
Nationality: Australia, New Zealand
Expertise: M&E / Value for Money

Qualifications:

Qualification	Institution	Year
MSc, Evidence-Based Health Care	University of Oxford	2013-14
MSc, Infectious Diseases	London School of Hygiene and Tropical Medicine	2006-2009
PhD, Economic Evaluation	University of Queensland	1993-1996

Countries of Experience: Bangladesh, Cambodia, China, Cook Islands, Federated States of Micronesia, Fiji, Georgia, Jordan, India, Indonesia, Kenya, Kiribati, Laos, Malaysia, Marshall Islands, Mongolia, Myanmar, Nepal, Pakistan, Papua New Guinea, Philippines, Samoa, Solomon Islands, South Africa, Sri Lanka, Tanzania, Thailand, Tonga, Tuvalu, United Kingdom, United States of America, Vanuatu, Vietnam, Zimbabwe, Australia

Current Affiliations:

Market Access and Economics Advisor, Royal Australasian College of Surgeons (2014-current)
 Senior Research Fellow, Centre for the Health Economy, Australia (2016-)
 Technical Review Panel, Global Fund to Fight AIDS, TB and Malaria (2016-)
 Proposal Review Committee, UNITAID, (2018-)
 Global Assessor, Royal Society of Tropical Medicine and Hygiene grants program, (2019-)
 Member, High Risk Human Research Ethics Committee, University of Sydney (2015-)
 Director, eSYS Development (consulting company), Australia (1995-)

Employment History:

Strong knowledge of health outcomes research to support market access. Includes review of clinical trials, retrospective or prospective observational studies, cross-sectional surveys of patients, validation of patient-reported outcomes/health-related quality of life assessments, systematic review & meta-analysis using software such as RevMan; and assessing quality of the evidence using Cochrane GRADE tools. Development of Markov models, cost of illness models, treatment patterns analyses, and budget impact analysis tools/services to assist reimbursement and market access decision making.			
Royal Australasian College of Surgeons	Royal Australasian College of Surgeons, 9/14-Current -Health Technology Assessment in Australia and Switzerland -Systematic review to define population, interventions, comparators, and outcomes relevant for economic and financial analysis -Leading data collection for primary endpoints & developing TreeAge and Excel models -Collaboration with internal and external partners - including academic research organizations, industry associations and other stakeholder groups	Australia	9/14-current
Centre for the Health Economy, Australia	External Evaluation for the Australian Pharmaceutical Benefits Advisory Committee which involves: -Evaluating value dossiers submitted for local reimbursement and pricing decisions. -Analyzing the clinical and economic evidence presented in submissions using TreeAge/Excel for Markov Modelling and STATA for extrapolation of survival data	Australia	10/16-current
KPMG Health, Aging and Human Services Advisory	Supporting the Australian practice which is active in: -Pricing, funding and resource allocation models -Performance measurement frameworks which included clinical pathway and Markov modelling for the National Mental Health Commission	Australia	9/14-11/14

Value for Money (VfM) analysis to prioritize investment for maximum impact. VfM analysis undertaken at unit prices of commodities such as pharmaceuticals and health products, measurement of standardized service delivery unit costs for key interventions & linking unit costs to health benefit impact (eg. cost per life-year saved or per disability-adjusted life-year). VfM results used to support scale-up of evidence-based interventions among vulnerable populations & to enhance integration of infectious disease programs into the delivery of other health services.			
Value for money analysis of AusAID's Australia-Africa Community Engagement Scheme	<ul style="list-style-type: none"> -Developed a framework to analyze the costs and benefits of the overall program. Grants included: water and sanitation, mother and child health, HIV/AIDS, food security, law and justice; and reproductive health. -Provided recommendations for appropriate mechanisms to track value for money through the implementation of the program 	Africa Regional	08/11-3/12
Estimation of Global Fund Unit Costs and Cost-Effectiveness, Global Fund, Geneva	<ul style="list-style-type: none"> -Estimated Global Fund Unit Costs and Cost-Effectiveness of Resources for IDUs, MSM, Sex Workers and ART treatment in Europe and Asia -Assessed Global Fund financial resources and unit costs for HIV prevention and treatment across all Central European and Asian Round 1-6 grants; and -Estimated the cost-effectiveness of Asian and Central European harm reduction GF programs, sex worker/MSM prevention using the Asian Epidemic Model 	Global Fund, Geneva	04/09-09/09
Harm Reduction Resource Needs in Asia, UNODC, Bangkok	<ul style="list-style-type: none"> -Estimation of resource availability, resource needs and gaps for people who inject drugs in Asia. Involved: -Tracking of the financial resources available for harm reduction -Estimated the funding required to implement a comprehensive package of HIV prevention, treatment and care interventions for injecting drug users across Asia. 	Asia Regional	01/09-05/09
Economics of Counterfeit Infectious Disease Medicines in the Mekong Asian Development Bank Technical Assistance	<ul style="list-style-type: none"> -Reviewed and collate existing data about the prevalence of counterfeit HIV, TB and malaria medicines in Mekong region and economically quantify their impact. -Quantification focused on estimating the financial value of counterfeit drug sales, along with estimating the economic costs to households and overall national economies from the usage of drugs with low efficacy. -Model developed to estimate the economic ramifications (increased days of lost work, care costs and elevated health expenditures) from the use of counterfeit TB, malaria and HIV medicines in Laos, Cambodia and Vietnam 	Cambodia, Laos, Myanmar, Vietnam	08/08 - 01/09
Financing Needs for HIV/AIDS Prevention and Care in Asia, UNAIDS/ADB	<p>Financial and economic analysis of HIV/AIDS impact in Asia and the Pacific. Estimates were prepared for different levels of HIV/AIDS prevalence (using Goals Model - Futures Group). Economic impact research focused on:</p> <ul style="list-style-type: none"> -Sectoral levels, especially on health services, -Macro levels, demographic indicators (adult mortality, life expectancy, infant mortality, disability adjusted life years) and gross domestic product, and -Household levels, including incomes, savings, assets, schooling and family size for different countries. <p>-Findings were launched at a press conference preceding the Bangkok 2004 AIDS Conference. Study featured in 5-page article in Far Eastern Economic Review and International Herald Tribune</p>	Asia Regional	07/03 - 09/04

Employer/Project	Position	Place	Dates
Evaluation at the operational level has involved analysis of the effectiveness & efficiency of integrated health service delivery, health information systems, procurement supply management systems, human resources for health and financial management systems of projects, along with assessment of outcomes, and impact /sustainability. Evaluation has included appraisal of M&E indicators and systems (including selection and definition of indicators), verification and reporting. Methods have involved use of OECD DAC evaluation criteria, mixed methods, qualitative approaches, semi-structured interviews, online and face-to-face surveys, economic & financial analysis & poverty impact assessment.			
Project Performance Evaluation - Pacific HIV Response Fund, Secretariat of the Pacific Community	<ul style="list-style-type: none"> -Assessed the overall performance and impact of the Response Fund as a fund vehicle for controlling HIV/STIs in the Pacific. -Evaluated fund administration, management, and delivery role for the Principle Recipient. -Assessed capacity development and technical assistance. -Quantified financial and economic sustainability of the project and how the Response Fund has impacted target populations 	Fiji, Kiribati, Cook Islands	11/13-3/14
Evaluation of the Global Fund HIV Program in Georgia	<ul style="list-style-type: none"> -Determined the impact and outcome of the HIV program in Georgia to date. -Defined the most effective interventions being implemented. -Indicated expenditure implications for re-programming scenarios 	Georgia	11/12-01/13
Review of the National HIV Program in Laos, Ministry of Health Laos	<ul style="list-style-type: none"> -Reviewed of the targets of the Laos National Strategy. -Evaluated different delivery models against best practices, feasibility, effectiveness, quality, value for money and coordination 	Laos	3/12-5/12
Evaluation of Tibet Health Sector Support Program, AusAID, Tibet.	<ul style="list-style-type: none"> -Primary responsibility for evaluating overall program design, program management, M&E & gender -Directed team inputs and responsibilities, coordinating the in-country mission logistics and delivering quality reports 	China, Tibet	5/10-8/10
Project Performance Evaluation - Decentralized Health Services Project, Asian Development Bank	<ul style="list-style-type: none"> -Prepared evaluation report for primary health development loan which included assessment of performance of relevant agencies. -Identified institutional development and capacity development achievements. -Compliance with safeguard policies. -Assessed contribution of the Project to poverty reduction. -Identified lessons derived from the project design, implementation, and completion 	Indonesia	12/12-3/13
Mid Term Review - Rural Primary Health Services Delivery Project, Asian Development Bank	<ul style="list-style-type: none"> -Evaluated scope, implementation progress, changes in implementation arrangements and achievement of scheduled project targets. -Assessed the efficiency on the use of consultants & resources to deliver the desired project outputs -Identified the best practices implemented in the project and lessons learned to date. -Provided recommendations on the changes/re-scoping based on the outcomes of the evaluation. -Conducted initial assessment on the current health sector reform needs of the country. -Identified capacity and political environment which could support and hinder health reforms. -Conducted initial assessment on how private investors could be involved in improving health service delivery and infrastructure. -Provided recommendations on the health sector reforms required by PNG to improve its overall health system 	Papua New Guinea	3/16-5/16

Impact assessment at a strategic level has involved evaluation and development of infectious disease strategies and responses which reflect differentiated approaches for diverse country contexts, planning for sustainability of programs and creating an equitable response to HIV, TB and malaria.			
"Bending the Curve" - Asia Regional TB Strategy, WHO SEARO	<ul style="list-style-type: none"> -Evaluation of private sector engagement (PSE), intensified case finding (CF) and preventive therapy (IPT) packages to achieve the End TB target milestones -Unit cost estimation and development of dynamic model with Imperial College London and the Public Health Foundation of India which examines the impact of selected interventions in reducing the TB burden -Results presented at March 2017 meeting in Delhi, where Health Ministers from 11 countries signed a Call for Action for Ending TB in the region 	WHO SEAR Asia Regional	1/17-5/17
Strengthening Regional Response to Malaria in Asia and the Pacific - Asia Pacific Leaders Malaria Alliance	<ul style="list-style-type: none"> -Prepared terms of reference and materials for the Asia Pacific Leaders Malaria Alliance (APLMA) financing task force -Included reviewing estimates of funding needs and gaps in the region for countries & commissioning modelling to quantify the implications of changes in the global financing environment for country level malaria financing. 	Asia Regional	2/14-4/14
Commission for AIDS in Asia	<ul style="list-style-type: none"> -Supported the Commission for AIDS in Asia Secretariat undertaking economic and financial evaluations, briefings at consultations and preparing the final report launched by the UN Secretary General in March 2008. -Commission held five sub-regional and regional consultations, meeting more than 30 experts and 600 individuals and governmental and civil society groups, as well as reviewing more than 5,000 published and unpublished studies. -Commission recommended specific government actions on prevention, treatment and care services - focusing prevention programs to the sex trade and on drug use. 	Asia Regional	1/07-12/07
Member of technical review committees reviewing health funding proposals across a diverse range of country contexts - including resource constrained environments. Recommendations based on factors such as measures of health coverage and health outcomes, ethics and broader considerations of implementation success based on impact, effectiveness, risk analysis and value-for-money.			
Global Fund to Fight AIDS, TB and Malaria - Technical Review Panel	<p>Serving member of technical review panel which:</p> <ul style="list-style-type: none"> -Involves assessing the strategic focus, technical soundness and potential for impact of funding requests in accordance with the Global Fund strategy; and -Identifying issues and strategic actions that need to be addressed during the grant-making process and implementation 	Global Fund, Geneva	11/16-current
GAVI Independent Review Committees - Member	<p>Member of Monitoring, New Vaccines, Health Systems Strengthening Committees. Provided:</p> <ul style="list-style-type: none"> -Country grant renewal recommendations to the Board; and mid-term/long-term programmatic, financial and policy recommendations for US\$ 7.3 billion 2011-2015 portfolio -Independent and systematic review of new proposals and monitoring of existing support to countries; -Budget impact analysis, assessment of outcomes for pneumococcal, rotavirus, Pentavalent (DTP-hep B-Hib), Human papillomavirus (HPV), polio, measles, rubella, yellow fever, and Meningitis A vaccines 	GAVI, Geneva	06/12-1/14

High Risk Human Research Ethics Committee, University of Sydney	-Committee has the objectives of protecting the mental and physical welfare, rights, dignity and safety of human participants of research and the safety of staff and students conducting research -Facilitating ethical research through efficient and effective review processes, in accordance with the National Statement on Ethical Conduct in Human Research	Sydney Australia	11/15-current
Design and costing of M&E systems during the preparation of health loans for development banks and governments targeting infectious diseases and health systems strengthening. Design work included management of international and domestic technical experts, leadership of cross functional and multi-country teams, facilitation of international meetings at ministerial level, excellence in writing and data analysis, along with oral communication skills for broad and diverse audiences.			
Asian Development Bank project designs	-Greater Mekong Sub Region Communicable Disease Control Project, Asian Development Bank and World Health Organization, 12/04-4/05, \$35 million -Health Care in the South Central Coast Region, Asian Development Bank Loan Preparation, Vietnam, 04/07-08/07, \$72 million loan. -Capacity Building for HIV/AIDS Prevention in Laos and Vietnam, Asian Development Bank Loan Preparations, Viet Nam and Laos, 5/12-8/12, \$20 million loan -Nutrition Improvement through Community Empowerment, Asian Development Bank Loan Preparation, Indonesia, 05/06-12/06, \$90 million -HIV/AIDS Prevention and Control in Rural Development Enclaves, Asian Development Bank, Papua New Guinea, 05/06-08/05, \$21 million -HIV/AIDS Prevention and Capacity Development in the Pacific Project, Asian Development Bank, Pacific Region, 07/05-09/05, \$12 million grant -HIV/AIDS Prevention among Youth, Asian Development Bank Grant, Viet Nam, 01/06 - 02/06, \$20 million grant.	Asia & Pacific	2003-2012

Relevant Publications:

- Commission for AIDS in Asia, 2008. Redefining AIDS in Asia - Crafting an effective response, 26 March, 2008.
<http://www.unaids.org/en/resources/presscentre/featurestories/2008/march/20080326asiacommission>
- McLeod, R. 2008. Economic Costs of Counterfeit Medicines in the Mekong, Mekong Health Summit, Guilin, Guangxi
- Komatsu R, McLeod R, Sarkar S, et al., 2010, Asia can afford universal access for AIDS prevention and treatment, Aids, Vol:24, ISSN:0269-9370, S72-S79
- Bergenstrom A, McLeod R, Sharma M, et al., 2010, How much will it cost? Estimation of resource needs and availability for HIV prevention, treatment and care for people who inject drugs in Asia, International Journal of Drug Policy, Vol:21, ISSN:0955-3959, Pages:107-109

Additional Information:

- Fellow Royal Society of Tropical Medicine & Hygiene
- Health Technology Assessment International (HTAi)
- International Health Economics Society
- International Society for Pharmacoeconomics and Outcomes Research